The tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023
LONDON, Jan. 7, 2019 /PRNewswire/ -- About this market
Strategic alliances to trend in the market. The growing prevalence of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. Technavio' s analysts have predicted that the tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023.
Download the full report: https://www.reportbuyer.com/product/5691278
Market Overview
Recent approvals of TKIs
Many TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.
Side effects of TKIs
Despite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.
For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.
Download the full report: https://www.reportbuyer.com/product/5691278
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/the-tyrosine-kinase-inhibitors-market-will-register-a-cagr-of-more-than-8-by-2023-300773875.html
SOURCE ReportBuyer
